The role of ganciclovir for the management of cytomegalovirus retinitis in HIV patients: Pharmacological review and update on new developments

ALICE TSENG PharmD, MICHELLE FOISY PharmD


OBJECTIVE: To review the pharmacology and pharmacokinetics of intravenous, oral and intraocular ganciclovir, and to discuss the role of these various formulations in the management of cytomegalovirus (CMV) retinitis in AIDS patients.

DATA SOURCES: A MEDLINE search (1987 through November 1995) of English-language literature using the main medical subject headings 'ganciclovir' and 'cytomegalovirus', and the subheading 'acquired immunodeficiency syndrome'. Relevant articles were also selected from references of identified articles. Abstracts from recent medical conferences of infectious diseases, pharmacology and human immunodeficiency virus were screened for additional data.

STUDY SELECTION AND DATA EXTRACTION: All articles and abstracts discussing the use of ganciclovir for the management or prophylaxis of CMV retinitis in AIDS patients were considered for inclusion. Pertinent information, as judged by the authors, was selected and synthesized for discussion.

DATA SYNTHESIS: Ganciclovir has demonstrated virustatic activity against CMV, and is often administered 5 mg/kg intravenously every 12 h as first-line therapy for CMV retinitis. Intravenous maintenance therapy at 5 mg/kg daily is usually effective at delaying retinitis progression for approximately 60 to 70 days. Neutropenia and thrombocytopenia are observed frequently, often necessitating interruption or discontinuation of therapy. Local drug administration may delay disease progression even further, and may be considered for patients who are intolerant to or failing intravenous therapy. However, systemic ganciclovir should be encouraged to reduce the risk of developing contralateral eye or end-organ CMV disease. Oral ganciclovir at 1 g tid is almost as effective as intravenous ganciclovir 5 mg/kg/day in delaying retinitis progression and is associated with fewer line-related complications. Absorption, drug interactions, cost and compliance should also be considered.

CONCLUSIONS: Until recently, ganciclovir was available only for intravenous use. Recent developments allow for intraocular and oral administration of this agent. A clear understanding of the advantages and disadvantages of these new formulations is required in order to select the most appropriate product for managing CMV retinitis in AIDS patients.

Key words: AIDS, Ganciclovir, Cytomegalovirus retinitis

The Toronto Hospital, The Wellesley Hospital and Faculty of Pharmacy, University of Toronto, Toronto, Ontario

Correspondence and reprints: Dr Alice Tseng, Immunodeficiency Clinic, The Toronto Hospital – General Division, College Wing, G-315, 101 College Street, Toronto, Ontario MSG 2C4. Telephone 416-340-5077, fax 416-340-4890

Received for publication December 14, 1995. Accepted March 13, 1996
Rôle du ganciclovir dans le traitement de la rétinite à cytomégalovirus chez les patients VIH-positifs : survol pharmacologique et mise à jour

OBJECTIF : Revoir la pharmacologie et la pharmacocinétique du ganciclovir par voies intraveineuse, orale et intraoculaire et discuter du rôle de ces diverses formules sur le traitement de la rétinite à cytomégalovirus (CMV) chez des sidéens.


SÉLECTION DES ÉTUDES ET EXTRACTION DES DONNÉES : Tous les articles et résumés abordant l’emploi du ganciclovir pour le traitement ou la prophylaxie de la rétinite à CMV chez les patients sidéens ont été étudiés en vue de leur inclusion. Les renseignements pertinents selon le jugement des auteurs ont été sélectionnés et synthétisés aux fins de la discussion.

SYNTHÈSE DES DONNÉES : Le ganciclovir a démontré une activité virustatique contre le CMV et est souvent administré à raison de 5 mg/kg par voie intraveineuse à toutes les 12 heures, comme traitement de première ligne de la rétinite à CMV. Le traitement d’entretien intraveineux à raison de 5 mg/kg par jour est habituellement efficace à retarder la progression de la rétinite pendant environ 60 à 70 jours. La neutropénie et la thrombocytopenie sont souvent observées et justifient fréquemment l’interruption ou la cessation du traitement. L’administration locale du médicament peut retarder davantage la progression de la maladie et peut être envisagée chez des patients qui ne tolèrent pas le traitement intraveineux ou si ce dernier échoue. Toutefois, le ganciclovir par voie systémique doit être favorisé afin de réduire le risque d’installation d’une maladie à CMV à l’œil controlatéral ou à un organe cible. Le ganciclovir oral à 1 g t.i.d. est presque toujours aussi efficace que le ganciclovir par voie intraveineuse à 5 mg/kg par jour pour retarder la progression de la rétinite et est associé à un moins grand nombre de complications. L’absorption, les interactions médicamenteuses, le coût et l’observance thérapeutique doivent également être tenus en ligne de compte.

CONCLUSIONS : Jusqu’à récemment, le ganciclovir n’était offert que pour un usage intraveineux. De récents progrès accomplis permettent désormais l’administration intraoculaire et orale de cet agent. Il faut bien comprendre les avantages et les inconvénients de ces nouvelles formules pour choisir le produit le plus approprié pour le traitement de la rétinite à CMV chez les sidéens.

Ganciclovir sodium (9-[1,3-dihydroxy-2-propoxymethyl]guanine or DHPG) is a synthetic nucleoside analogue of 2′-deoxyguanosine. Ganciclovir possesses activity against members of the Herpesviridae family as well as other DNA viruses. Approved indications for its use include treatment of cytomegalovirus (CMV) retinitis in immunocompromised hosts, including those with AIDS and organ transplantation recipients (1). Other potential uses of ganciclovir are for CMV disease involving the gastrointestinal tract, the lung and the liver and for the prevention of CMV in transplant recipients and AIDS patients. This article will provide a pharmacological review of ganciclovir and focus on its role in the management of CMV retinitis in AIDS patients.

PHARMACOLOGY

Structure-activity relationships: Ganciclovir is structurally related to acyclovir and the naturally occurring purine nucleoside analogue 2′-deoxyguanosine. It differs from acyclovir by the addition of a second terminal hydroxymethyl group at the C-2 position of the acyclic side-chain on the ribose ring. Compared with acyclovir, this addition confers increased activity against CMV and less selectivity for viral DNA (2).

Mechanism of action: For antiviral activity, ganciclovir must be converted to the triphosphate form intracellularly through a series of enzymatic reactions. Viral thymidine kinase (in herpes simplex virus [HSV] types 1 and 2 and varicella zoster virus [VZV]) or host-encoded deoxyguanosine kinase (for CMV and Epstein-Barr virus [EBV]) are responsible for catalyzing the rate-limiting reaction of ganciclovir to ganciclovir monophosphate. Subsequent conversion of the monophosphate to the diphosphate form occurs via cellular guanylate kinase. Phosphoglycerate kinase and several cellular kinase enzymes catalyze the final reaction of the diphosphate to the triphosphate form. In the active triphosphate form, ganciclovir inhibits viral DNA polymerase and can be incorporated into the growing DNA chains as a false nucleotide. Viral replication is inhibited as a result of both the termination of DNA chain elongation and the formation of a mutant DNA chain. Although ganciclovir triphosphate displays relative specificity for viral DNA polymerases compared with host cellular DNA polymerase, uninfected host cells are also capable of producing small amounts of ganciclovir triphosphate. The accumulation of ganciclovir triphosphate in intact host cells may result in myelosuppression (2,3).

Spectrum of activity: Ganciclovir displays virustatic in vitro and in vivo activity against various members of the Herpesviridae family. While ganciclovir is used primarily for CMV infections, it also exhibits activity against HSV-1, HSV-2, human herpesvirus type 6, EBV and VZV (4). The concentration of drug required to produce 50% inhibition of viral plaque formation (ID50) of ganciclovir susceptible strains of CMV ranges from 0.6 to 7.0 μM (mean 3.6) (5–11). In contrast, acyclovir is relatively inactive against CMV, with ID50 values of 10 to 200 μM (2). For viral strains of HSV and VZV that are acyclovir-resistant due to mutations in thymidine kinase or DNA polymerase, ganciclovir may demonstrate in vitro activity (12,13). Suggested breakpoints for clinical CMV isolates are as follows: fully sensitive ID50 5 μM or less; intermediate ID50 6 to 10 μM; and resistant
Creatinine clearance (CrCl) can be calculated by the formula:
\[
\text{CrCl (mL/min)} = \left(\frac{140 - \text{age in years}}{\text{Ideal body weight in kg}}\right) \times \frac{60}{\text{serum creatinine in } \mu\text{mol}}.
\]
Adapted from reference 1.

### TABLE 1
Ganciclovir dosing guidelines for renal impairment

<table>
<thead>
<tr>
<th>Creatinine clearance (mL/min)</th>
<th>Induction</th>
<th>Intravenous dose</th>
<th>Maintenance</th>
<th>Oral maintenance dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥70</td>
<td>5 mg/kg every 12 h</td>
<td>5 mg/kg every 24 h</td>
<td>1000 mg tid or 500 mg every 3 h (6 times/day)</td>
<td></td>
</tr>
<tr>
<td>50-69</td>
<td>2.5 mg/kg every 12 h</td>
<td>2.5 mg/kg every 24 h</td>
<td>1500 mg daily or 500 mg tid</td>
<td></td>
</tr>
<tr>
<td>25-49</td>
<td>2.5 mg/kg every 24 h</td>
<td>1.25 mg/kg every 24 h</td>
<td>1000 mg daily or 500 mg bid</td>
<td></td>
</tr>
<tr>
<td>10-24</td>
<td>1.25 mg/kg every 24 h</td>
<td>0.625 mg/kg every 24 h</td>
<td>500 mg daily</td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>1.25 mg/kg 3 times weekly, following hemodialysis</td>
<td>0.625 mg/kg every 24 h 3 times weekly, following hemodialysis</td>
<td>500 mg 3 times weekly, following hemodialysis</td>
<td></td>
</tr>
</tbody>
</table>

ID₅₀ greater than 10 µM or four times the pretreatment value (14,15).

**Synergy:** In vitro synergy of fosfomycin and ganciclovir against CMV has been observed (16). Clinically, the combination may result in lower doses of each agent used or it may be used to overcome reported resistance to both agents alone.

**Development of resistance:** Although the incidence and clinical significance of ganciclovir resistance remain to be fully elucidated, one study reported an 8% incidence of ganciclovir-resistant CMV strains in AIDS patients receiving therapy for longer than three months (17). Several mechanisms of viral resistance may exist. Since antiviral resistance is dependent on ganciclovir triphosphate, resistance may develop from decreased phosphorylation of ganciclovir. Thus, a decrease in or lack of viral thymidine kinase or alterations in substrate specificity of the enzyme may occur (2,17). Ganciclovir may or may not display cross-resistance with fosfomycin or acyclovir (2). The possibility of viral resistance should be considered in patients who exhibit poor clinical response to therapy or in those with persistent viral shedding (17).

### PHARMACOKINETICS

Previously, ganciclovir was available only for parenteral administration. New developments, however, have now allowed this agent to be administered orally as well as intracuually.

**Absorption:** The oral bioavailability of ganciclovir is quite low and is estimated to be approximately 6% to 9% (18,19). The absorption of oral ganciclovir is increased when taken with food, with an average increase in the area under the curve (AUC) of 22% (20). When taken with food, both intrapatient and interpatient variability are low (19). Absorption becomes nonlinear with higher daily doses (6 g/day) and with larger doses (1500 to 2000 mg/dose) (18,19). Bioavailability is comparable for regimens of 500 mg orally every 3 h, six times daily, and 1 g orally every 8 h (19).

**Distribution:** Ganciclovir is only 1% to 2% bound to plasma proteins (2). The volume of distribution after initial and steady state dosing is 15.3 L/1.73 m², and 30 to 70 L, respectively (21). Ganciclovir concentrations in the kidneys are three- to sevenfold higher than in heart blood. Concentrations observed in the liver, testes and lung are similar to heart blood concentrations (6). Cerebrospinal fluid concentrations are estimated to be 24% to 67% of serum concentrations (22). Following intravenous ganciclovir, vitreous fluid concentrations are often lower than corresponding plasma concentrations (7,23,24). The volume of distribution in the vitreous is approximately 11.7 mL after a 200 µg intravitreal injection (25).

It is unknown whether ganciclovir is distributed into human milk. However, considering its large volume of distribution, low protein binding and structural similarity to acyclovir, which has been shown to penetrate human milk, ganciclovir may penetrate milk (2). Since the potential for serious adverse effects in the nursing infant exists, the manufacturer recommends that ganciclovir should not be given to breast-feeding mothers. Nursing may be resumed 72 h after the last dose (1).

**Elimination:** Up to 100% of ganciclovir is eliminated unchanged in the urine; thus, patients with renal dysfunction require a dose reduction (26) (Table 1). In patients with normal renal function, the mean elimination half-life after multiple doses is 2.5 to 4.2 h (6,22,26,27). A half-life of 9.5 to 29 h has been reported in patients with renal insufficiency (26). Following a 200 µg intravitreal injection, half-life in the vitreous was estimated to be 13.3 h (25).

Approximately 53% of ganciclovir is removed from plasma after 4 h of hemodialysis (27) and almost 90% of ganciclovir is removed by continuous venovenous hemodialysis (28).

**Drug concentrations:** Table 2 summarizes serum concentrations obtained after intravenous, oral and intravitreal administration of ganciclovir.

Plasma drug concentrations: In a prospective study of 28 AIDS patients receiving intravenous ganciclovir for CMV retinitis, mean plasma ganciclovir concentrations were 4.00 µM for those receiving induction therapy (5 mg/kg bid) and 1.69 µM for those receiving maintenance therapy (5 mg/kg/day) (23).

Oral regimens of 500 mg every 3 h, six times daily and 1 g every 8 h yielded mean peak concentrations of 3.92 to 4.70 µM, mean trough concentrations of 0.78 to 1.18 µM and mean AUCs(0-24 h) of 60.5 to 62.3 µM·h (19). In the same study, administration of a single dose of intravenous ganciclovir (5 mg/kg) resulted in a mean peak of 52.4 µM, mean trough (computed as the mean of the 0-hour and 24-hour concentrations) of less than 0.2 µM (ie, below the quantification limit of the assay) and mean total AUC of 86.6 µM·h (19).
TABLE 2
Ganciclovir concentrations

<table>
<thead>
<tr>
<th>Dose and route of administration</th>
<th>Plasma</th>
<th>Intravitreal</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean (µM)</td>
<td>Peak (µM)</td>
</tr>
<tr>
<td>5 mg/kg iv x 1</td>
<td>32.4</td>
<td>&lt;0.2</td>
</tr>
<tr>
<td>5 mg/kg iv bid</td>
<td>4.00±2.09</td>
<td>–</td>
</tr>
<tr>
<td>5 mg/kg iv daily</td>
<td>1.69±1.69</td>
<td>–</td>
</tr>
<tr>
<td>5 mg/kg iv 1-2 times daily</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>1 g orally tid or 500 mg orally 6x/day</td>
<td>–</td>
<td>3.92-4.70</td>
</tr>
<tr>
<td>200 µg inj every 3 days x 15 days</td>
<td>&lt;0.40</td>
<td>–</td>
</tr>
<tr>
<td>1 µg/h implant</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

AUC Area under the curve; inj Intravitreal injection; iv Intravenous

Systemic absorption of ganciclovir after intravitreal injection is minimal (25).

Intravitreal drug concentrations: In the treatment of CMV retinitis, achieving inhibitory concentrations of ganciclovir in the vitreous fluid of the eye may play an important role in the successful suppression of retinal viral replication. The relationship between plasma and intravitreal drug concentrations has not been fully elucidated. Following intravenous drug administration, intravitreal concentrations are assumed to be related to plasma AUC. With direct administration of drug into the eye, achievable local concentrations may be much higher, due to the vitreous fluid’s small volume of distribution and to longer elimination.

After intravenous administration: Kupperman et al (24) measured ganciclovir levels in vitreous samples obtained intraoperatively from 23 eyes of 22 AIDS patients with retinal detachments associated with CMV retinitis. The mean extent of retinitis at the time of surgery was 44±21%. Seventeen patients had been on maintenance ganciclovir, and five patients had been receiving induction therapy for longer than two weeks before surgery. The overall mean intravitreal ganciclovir concentration for all samples was 3.76±1.53 µM. There was no correlation between the intravitreal ganciclovir level and the extent of either retinitis or retinal detachment. There was also no statistically significant difference in mean intravitreal concentrations between patients receiving induction versus maintenance therapy, although this may be a reflection of the small sample size. The authors concluded that mean intravitreal ganciclovir concentrations obtained with intravenous administration were below the ID_{50} of many clinical CMV isolates and may be associated with disease progression while the patient is on maintenance therapy (24).

More recently, Arevalo et al (23) prospectively studied 28 AIDS patients with CMV retinitis and retinal detachment. Undiluted vitreous and plasma samples were taken at the time of retinal reattachment surgery. Twenty-four vitreous samples were obtained from patients receiving intravenous ganciclovir 10 mg/kg/day and 30 from patients receiving intravenous ganciclovir 5 mg/kg/day. Analyses were done to correlate drug concentration with time of administration of last dose. In patients receiving induction therapy, the mean intravitreous ganciclovir concentration was 4.74±1.49 µM, versus 3.29±1.84 µM in patients receiving maintenance therapy (P=0.005). Again, there was no significant correlation between vitreous drug concentration and the extent of either retinitis or retinal detachment (23).

After oral administration: No data are available regarding intravitreal drug concentrations following oral ganciclovir administration. Since AUCs achieved with oral regimens are approximately 70% of those achieved with intravenous ganciclovir (19), one may presume that intravitreal levels will be proportionally lower.

Intravitreal administration: In a patient who received 200 µg injections every three days for 15 days, the concentration of ganciclovir in the intravitreal fluid immediately post-injection was 63.86 µM, while plasma ganciclovir concentrations remained less than 0.4 µM (25). At 51.4 and 97.3 h, intravitreal ganciclovir concentrations were 4.6 and 0.41 µM, respectively. The half-life in vitreous fluid was estimated to be 13.3 h (versus serum half-life of 2 to 4 h), suggesting that intravitreal injections should be given twice weekly to ensure that ganciclovir concentrations remain above the mean ID_{50} of CMV for approximately 62 h (25).

Martin et al (29) performed a randomized controlled clinical trial to assess the safety and efficacy of 1 µg/h of ganciclovir intraocular implants for the treatment of newly diagnosed CMV retinitis in 26 AIDS patients. Intraocular drug levels were measured from vitreous samples obtained at the time of implant exchange or retinal detachment surgery. The mean vitreous drug level in eight eyes was 16.06 µM (29).

**DRUG INTERACTIONS**

Table 3 summarizes common drug interactions with ganciclovir, and provides recommendations for management and monitoring.

**Zidovudine:** Concomitant administration of zidovudine (600 to 1200 mg daily) and ganciclovir (5 mg/kg once or twice daily) resulted in hematological toxicity in 82% of AIDS patients, with neutropenia being the most common side effect (55%) (30). In a controlled pharmacokinetic study, administration of zidovu-
dine 100 mg orally every 4 h, five times daily, with oral ganciclovir 1 g every 8 h resulted in a 14.5% increase in zidovudine AUC (P=0.032) (31). Changes in hematological parameters were not assessed in this study. In an open-label clinical trial, 113 patients (80 with AIDS, 33 with AIDS-related complex) were treated with zidovudine 200 mg orally every 4 h for a median duration of 152 days (range five to 386) (32). Multiple regression analysis indicated that concurrent ganciclovir was associated with an increased risk of anemia and thrombocytopenia.

Due to the potential for additive hematotoxicity, it is recommended that these agents not be given concomitantly during the induction phase of ganciclovir (1).

**Didanosine**: A significant two-way interaction has been demonstrated between didanosine (ddl) and oral ganciclovir. In a multiple dose crossover pharmacokinetic interaction study, 13 human immunodeficiency virus (HIV)-positive patients received ganciclovir 1 g orally every 8 h and ddl 200 mg orally every 12 h (31). Ganciclovir and ddl were administered both sequentially (ie, ddl 2 h before oral ganciclovir) and simultaneously to evaluate the effect of the ddl buffer on the absorption of ganciclovir. In the presence of ganciclovir, significant increases in ddl AUC were noted with both sequential and simultaneous administration (114.6% and 107.7%, respectively, P<0.001). In addition, the AUC of ganciclovir was decreased by 21.4% (P=0.002) when administered 2 h after ddl; no significant changes in renal clearance of either drug were observed (31).

In a randomized, three-way crossover trial, 13 asymptomatic HIV-positive males received the following regimens in random order: intravenous ganciclovir 5 mg/kg every 12 h for three days; ddl 200 mg orally every 12 h for three days; and the two agents in combination for three days (33). In the presence of ganciclovir, both the mean AUC and peak serum concentration of ddl increased significantly (70.4%, P<0.001, and 49.3%, P=0.024, respectively). No significant changes in time to maximum serum concentrations, half-life or renal clearance of ddl were observed. In the presence of ddl, a modest increase in ganciclovir AUC (6.2%, P=0.018) was noted (33). The mechanism for this interaction is unknown. Patients receiving both ddl and ganciclovir should be closely monitored for development of ddl-related toxicities (31,33).

**Probenecid**: Probenecid decreases the renal clearance of ganciclovir by competition for renal tubular secretion, resulting in an increase of ganciclovir AUC by approximately 50% (31). Administration of this combination is not recommended, for several reasons, including the potential for an increased risk of dose-related ganciclovir toxicities, the risk of side effects secondary to probenecid (eg, headache, gastrointestinal upset, rash) and the potential interference with renal elimination of drugs concomitantly administered.

### TABLE 3
Ganciclovir drug interactions

<table>
<thead>
<tr>
<th>Drug combination with ganciclovir</th>
<th>Common side effects/toxicity</th>
<th>Comments</th>
<th>Monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>AZT</td>
<td>↑risk of neutropenia, anemia</td>
<td>Hold AZT during induction therapy with ganciclovir. Reintroduce with caution during maintenance or switch to ddl/ddC</td>
<td>CBC with differential 3 times weekly initially, then weekly</td>
</tr>
<tr>
<td>Amphoterin B, dapsone, flucytosine, pentamidine iv, primaquine, pyrimethamine, TMP/SMX, trimetrexate</td>
<td>↑risk of bone marrow toxicity</td>
<td>Cautious use of combinations is warranted</td>
<td>CBC for blood dyscrasias</td>
</tr>
<tr>
<td>ddl</td>
<td>With oral ganciclovir: ↑ddl concentration &gt;100%; ↓ganciclovir concentration 20% with sequential administration</td>
<td>Potential for ↑ddl toxicity and ↓ganciclovir efficacy. Administer oral ganciclovir before/with ddl to minimize effect on ganciclovir absorption</td>
<td>ddl toxicity and progression of CMV disease</td>
</tr>
<tr>
<td>Imipenem</td>
<td>↑risk of seizures</td>
<td>Do not exceed 2 g/day of imipenem. Dose adjust both agents in renal failure</td>
<td>SCr, urea</td>
</tr>
<tr>
<td>Probenecid</td>
<td>↓ganciclovir clearance, leading to ↑ganciclovir AUC of 50%</td>
<td>Avoid concomitant use due to potential for ↑risk of dose-related ganciclovir toxicities, risk of probenecid side effects (eg, headache, gastrointestinal upset, rash) and interference with renal elimination of other drugs a patient may be taking concomitantly</td>
<td></td>
</tr>
</tbody>
</table>

**AUC** Area under the curve; **AZT** Zidovudine; **CBC** Complete blood count; **CMV** Cytomeglovirus; **ddl** Dideoxycytidine; **ddI** Didanosine; **iv** Intravenous; **SCr** Serum creatinine; **TMP/SMX** Trimethoprim/sulfamethoxazole
**Imipenem-cilastatin:** Generalized seizures have been reported in six patients receiving ganciclovir and imipenem-cilastatin together. The risks versus benefits should be considered before administration of the combination (2).

**Cyclosporine:** Nephrotoxicity may be increased when cyclosporine and ganciclovir are administered concomitantly (34).

**Others:** Agents that interfere with replication of rapidly dividing cell populations, such as bone marrow, spermatogonia and germinal layers of skin and gastrointestinal mucosa, may have additive toxicity when given in conjunction with ganciclovir and should be used with caution. Such agents include dapsone, parenteral pentamidine, amphotericin B, trimethoprim-sulfamethoxazole (TMP/SMX), flucytosine, vincristine, vincblastine and adriamycin (1). In vitro cytotoxicity assays with human embryonic lung (MRC-5) cells suggest that ganciclovir, dapsone, amphotericin B and TMP/SMX are all associated with reductions in cellular metabolism of 17% to 40% (35). While no synergy or antagonism was noted with these combinations, there is presumably still the risk of additive cytotoxicity with concurrent administration of these drugs.

**CLINICAL TRIALS**

**Management of CMV retinitis – Intravenous:** Ninety per cent of AIDS patients will experience progressive disease if CMV retinitis is left untreated, while 80% of cases respond initially to ganciclovir therapy (36). Since recrudescence of CMV can occur within a few weeks of completing induction therapy, lifelong maintenance therapy with either ganciclovir or foscarnet is recommended (37).

Results from numerous open-label clinical trials suggest that ophthalmological response rates of CMV retinitis to ganciclovir vary from 81% to 100% (2,38-41). To evaluate the clinical response to ganciclovir more accurately, a system was developed to assess CMV retinopathy outcome using serial retinal photographs and three factors: development of new retinal lesions, enlargement of preexisting lesions and a change in opacification of lesion borders (42). This system was used to assess disease outcome in a controlled retrospective comparison of ganciclovir-treated versus untreated historical controls. Treatment with ganciclovir was associated with a reduction in disease progression in treated compared with untreated patients. Ganciclovir treatment was also associated with greater preservation of visual acuity (42). Data from these studies led to the licensure of ganciclovir for the treatment of CMV retinitis in AIDS patients in 1989.

In a randomized, comparative, multicentre study in AIDS patients with CMV retinitis, ganciclovir (5 mg/kg every 12 h for two weeks followed by 5 mg/kg daily adjusted for renal function) was compared with foscarnet therapy (60 mg/kg every 8 h for 14 days followed by 90 mg/kg/day adjusted for renal function) (43). Though the two treatment groups were equally efficacious in preventing the progression of retinitis, the overall survival was lower in the ganciclovir group (8.5 months) than in the foscarnet group (12.4 months). The survival advantage observed with foscarnet may be due to a combination of its anti-HIV activity and more antiretroviral use in the foscarnet group. Of note, in patients with renal impairment (estimated creatinine clearance less than 1.2 mL/min/kg) ganciclovir was associated with improved survival relative to foscarnet (43). In light of these findings, foscarnet may be the initial therapy of choice in those with normal renal function. However, since foscarnet has a higher incidence of nausea, vomiting and general malaise than ganciclovir and is less convenient to administer, ganciclovir is often the preferred agent.

**Intravitreal:** Experience with intravitreal ganciclovir suggests that this route of administration may be effective in controlling disease progression in patients who are failing or are intolerant to systemic antiviral therapy.

The use of intravitreal ganciclovir injections was first described by Henry et al (25) in an AIDS patient with rapidly progressing bilateral CMV retinitis and marked bone marrow suppression. The patient received intravitreal injections of 200 µg every three days over a 15-day period followed by 200 µg weekly injections over a three-month period, for a total of 28 injections. Retinitis in both eyes responded to treatment; when the patient later died as a result of severe coagulopathy, postmortem vitreal cultures were negative for CMV (25).

Successful short term results were also observed in 11 AIDS patients (14 eyes) with progressing CMV retinitis despite prior intravenous ganciclovir therapy (44). All patients received one to seven intravitreal ganciclovir injections of 200 µg for up to two months. Improvement or stabilization of visual acuity was seen in 12 (86%) eyes. One case of retinal detachment occurred during this time (44).

Data on long term use (ie, eight to 14 months) of intravitreal ganciclovir in small numbers of patients suggest that this route of administration may be effective as maintenance therapy in patients unable to tolerate systemic therapy (45,46). However, little is known about the complications associated with repeated intravitreal injections. In addition, the lack of systemic therapy may place patients at risk of developing contralateral retinitis or extraocular CMV disease (29,47).

**Intraocular implants:** A sustained-release intraocular ganciclovir implant may be considered in patients who respond to intravitreal ganciclovir injections. The surgically implanted device releases a constant amount of ganciclovir into the eye over six to eight months, thus obviating the need for frequent intraocular injections. Although implants are convenient, they are also expensive (approximately $5,000 per implant). Early anecdotal experience in patients with progressing retinitis, despite intravenous ganciclovir therapy, suggested that intraocular implants were effective in resolving acute retinal inflammation and suppressing progression of retinitis for a mean of 70 to 123 days (48,49).

Martin et al (29) conducted a randomized, controlled trial to assess the safety and efficacy of immediate versus deferred therapy with a 1 µg/h ganciclovir implant for the management of newly diagnosed CMV retinitis. Twenty-six patients (30 eyes) with peripheral retinal lesions, no systemic CMV disease and no prior exposure to ganciclovir or foscarnet were enrolled. Patients with unilateral retinitis were randomized to receive either immediate therapy (ie, surgical insertion of the implant within 48 h) or deferred therapy (implant offered when progression occurred). If retinitis developed in the con-
trilateral eye, that eye was also randomized to immediate or deferred therapy with an implant. Patients with bilateral retinitis served as their own controls (ie, one eye received immediate therapy and the other received deferred therapy). The primary study end-point was progression of retinitis, defined as a border advancement of greater than 750 μm, or the appearance of a new lesion at least 750 μm in diameter. Secondary end-points included the development of contralateral retinitis, visceral CMV disease and death. Patients were monitored every two weeks by masked fundus photography, and implants were exchanged every 52 weeks. Patients who developed immediately sight-threatening retinitis or visceral CMV disease were given systemic antiviral therapy. Fourteen eyes received immediate therapy with the implant, while 16 eyes were randomized to receive deferred therapy. The median time to progression of retinitis was 15 days (range 14 to 59 days) in the deferred group, compared with an estimated 226 days in the immediate therapy group (P<0.00001) (29). In total, 39 eyes received an implant: 14 in the immediate therapy group, 14 in the deferred group who experienced progression, and 11 that developed contralateral retinitis during the follow-up period. The range of follow-up after treatment with the implant was 13 to 423 days. Final visual acuity was 20/25 or better in 34 of 59 eyes. Progression occurred in nine eyes. A number of these cases responded to either insertion of a new implant or to intravenous therapy for visceral disease (29). The risk of developing contralateral retinitis was 50% by 205 days of therapy: thus, in total 14 of 21 patients (67%) developed disease in the fellow eye. Biopsy proven visceral CMV disease (most often in the gastrointestinal tract or the lungs) developed in eight of 26 (31%) patients, at an estimated median of 248 days. All eight patients responded to intravenous ganciclovir. The median survival time was 295 days. Retinal detachment occurred in seven eyes (18%). All cases were associated with posterior vitreous detachment, possibly induced by surgery. The investigators concluded that, although the implant was efficacious in treating CMV retinitis, patients were at risk of developing retinitis in the fellow eye or extraocular disease (29).

Another randomized, controlled, multicentre trial was conducted by the Chiron Ganciclovir Implant Study Group (47) to evaluate the safety and efficacy of a sustained-release ganciclovir implant compared with standard intravenous ganciclovir therapy for the treatment of CMV retinitis. One hundred and eighty-eight patients with newly diagnosed CMV retinitis and no extraocular CMV disease were enrolled in the study; of these, 173 were eligible to receive treatment and were randomized to either a 1 μg/h (n=62) or 2 μg/h implant (n=55) or intravenous ganciclovir (n=56). The primary study end-point was progression of retinitis, which was defined as movement of retinitis borders of ±750 μm, or development of a new retinal lesion. Progression was determined by a central masked fundus photograph reading centre. Secondary end-points included development of retinitis in the fellow eye, development of extraocular CMV disease, quality of life, and death. Patients in the intravenous ganciclovir group who progressed were offered an implant.

The median duration of follow-up was 164 days in the 1 μg/h implant group, 153 days in the 2 μg/h implant group and 81 days in the intravenous group. Median time to progression was 216 days for the combined implant group versus 104 days for the intravenous ganciclovir group (P<0.0001). Patients receiving implants experienced a slight decrease in visual acuity in the immediate postoperative period; visual acuity returned to preoperative levels within two to four weeks. Other complications in the implant recipients included three cases (1.2%) of endophthalmitis, which led to loss of vision in two patients, as well as a significantly higher incidence of retinal detachments compared with the intravenous group (12% versus 5%, respectively). Retinal detachment occurred earlier (ie, within the first three months postsurgery) in the implant group, but the risk of retinal detachment increased with time (presumably as a reflection of disease progression) in the intravenous arm (47). The incidence of fellow eye involvement was 40% in the combined implant group at a median time of 87 days, compared with 16% in the intravenous group at a median time of 119 days (not statistically significant). Extraocular disease was significantly more frequent in the implant recipients (15.3%). There was no statistically significant difference in survival between the combined implant and intravenous groups (140 days and 150 days, respectively) (47).

Combined efficacy results showed a slightly shorter time to progression with the oral ganciclovir compared with intravenous ganciclovir. When progression was determined using masked retinal photographs, the mean times to progression were 62 to 66 days in the intravenous group versus 51 to 57 days in the oral group, for a difference of five to 12 days (95% CI) in favour of the intravenous group. With funduscopic assessment, the difference in mean time to progression was statistically significant: 100 days versus 76 days for the intravenous and oral groups, respectively (50-52). According to this method of assessment, the times to development of progression were longer and the differences between the treatment groups were larger, which may reflect investigator bias as well as decreased ability to detect progression compared with the use of serial photographs. There was no statistically significant difference between the treatment arms in terms of progression to bilateral retinitis or progression of disease into zone 1, development of new lesions in infected eyes, reduction in visual acuity or functional vision, time to treatment failure or survival (50-52).

The incidence of side effects was similar between the treatment groups except for the occurrence of sepsis (17% versus 6%), intravenous catheter-related events (22% versus 6%), neutropenia (25% versus 18%) and anemia (21% versus 12%) in the intravenous and oral groups, respectively. Overall, there was
no statistically significant difference between the groups in terms of safety related premature withdrawals from therapy (50-52). **Prophylaxis of CMV end-organ disease:** Spector et al (53) conducted a randomized, double-blind, placebo controlled study to evaluate the safety and efficacy of oral ganciclovir for prevention of CMV end-organ disease. Following a baseline ophthalmological examination, 725 HIV-positive, CMV-seropositive patients with low CD4 counts (either less than 50 cells/mL, or less than 100 cells/mL and a prior opportunistic infection) were randomized to receive either 1 g ganciclovir every 8 h or placebo orally. Patients were assessed every two months by dilated indirect ophthalmoscopy. The mean duration of therapy was six months. Preliminary intent-to-treat analysis showed a statistically significant reduction in CMV disease in patients receiving ganciclovir compared with those on placebo (16% and 30%, respectively, P=0.0001), which led to early termination of the study. Retinitis was the most common disease manifestation and occurred in 11% of ganciclovir recipients, compared with 20% of those on placebo (P=0.001). A significant difference in the time to development of CMV disease was noted with oral ganciclovir (RR 2.2, P=0.001). There was no difference in survival between the two groups. Neutropenia developed in a significantly higher proportion of oral ganciclovir patients than in those on the placebo (13% versus 6%) (53).

As part of the study protocol, urine cultures, and occasionally blood and/or semen cultures, were performed every two months while patients were receiving treatment. The incidence of positive cultures at baseline was similar for both groups (42% and 44% for ganciclovir and placebo patients, respectively). After two months, the number of positive cultures in the ganciclovir group was reduced by 50%, while the incidence remained constant in the placebo group. At 18 months, the average prevalence of positive CMV cultures during oral ganciclovir prophylaxis was 11%, compared with 46% for the placebo group. The last isolate recovered from each patient receiving at least 90 days of treatment was tested for ganciclovir susceptibility. To date, 39 isolates from patients receiving ganciclovir for a mean 251 days (range 112 to 564) have been tested (54). Of these, 36 isolates were fully sensitive, one was moderately sensitive and two were resistant. All isolates obtained from 10 patients receiving placebo for a mean of 313 days (range 112 to 519) were sensitive to ganciclovir. The two resistant CMV isolates (ID50 55.8 and 14.0 μM) were obtained from urine cultures after nine and 10 months of ganciclovir. After an additional four months of prophylaxis, both patients developed CMV retinitis, which was unresponsive to intravenous ganciclovir therapy. These preliminary data suggest a low overall prevalence of resistance following a mean 8.3 months of ganciclovir prophylaxis, and in two patients, resistant virus was later associated with treatment failure (54).

Another placebo controlled trial of oral ganciclovir was conducted by the Terry Beirn Community Programs for Clinical Research on AIDS (55). Between April 1993 and June 1994, 994 patients with a CD4 count of less than 100 cells/mm³ and a positive CMV serology or culture were enrolled and randomized to receive either oral ganciclovir 1 g tid (n=662) or a placebo (n=332). Unlike the previous prophylaxis study, baseline ophthalmological examinations were not performed, and subsequent examinations were conducted when patients experienced visual complaints, rather than at routine intervals. Following the interim results of the prophylaxis study by Spector et al (53) in September 1994, patients in the placebo group were allowed to switch to open-label oral ganciclovir. The mean duration of exposure to oral ganciclovir was 9.3 months for patients initially randomized to oral ganciclovir and 2.1 months for patients randomized to placebo. Based on intent-to-treat analysis with follow-up data to June 1995, the investigators did not find any significant differences between the two groups with respect to development of any confirmed CMV disease, CMV retinitis, CMV gastrointestinal disease or death. Furthermore, patients who received oral ganciclovir experienced significantly more adverse effects, including neutropenia, compared with those on placebo (25% versus 16%, P=0.001) (55).

In contrast to Spector et al (53), the investigators of this study concluded that their results did not support the use of oral ganciclovir for prophylaxis of CMV disease (55). However, other factors should be considered when interpreting these results. Absence of a baseline assessment may have resulted in inadvertent inclusion of patients with mild or peripheral CMV retinitis into the study, and the lack of regular ophthalmological examinations may have resulted in an underestimation of disease development. In addition, the crossover of patients from the placebo to the oral ganciclovir group may have made it more difficult to demonstrate confirmatory results between the treatment arms.

**PLACE IN THERAPY OF CMV RETINITIS**

Besides ganciclovir, foscarnet is the only other readily available agent in Canada for the management of CMV retinitis. Due to its better tolerability, shorter infusion time and increased convenience, ganciclovir is often preferred as a first-line agent. Until recently, ganciclovir was available only via intravenous administration for both treatment and maintenance therapy of CMV retinitis. The development of novel formulations of ganciclovir has increased the options available to patients. However, a clear understanding of the advantages and disadvantages of these new formulations is required in order to select the most appropriate therapy for patients.

Following induction therapy with intravenous ganciclovir, patients must deal with daily intravenous infusions on an indefinite basis. However, the majority of patients eventually have progression of retinitis while on maintenance treatment (43). Intravenous ganciclovir is usually effective at delaying CMV retinitis progression for approximately 60 to 70 days (43). Often, progression of retinitis may occur because of subtherapeutic intraocular drug levels. Therefore, reinstituting therapy at induction doses can be effective in halting disease progression; patients who respond may then require continued therapy with higher doses. One must be cognizant that these patients may be at higher risk of experiencing dose-related toxicities.
Intravitreal ganciclovir may be an alternative to intravenous ganciclovir in neutropenic and/or thrombocytopenic patients who are intolerant to foscarnet, or it may be used in combination with systemic therapy to achieve greater control of CMV retinitis (56). For patients who do not wish to receive frequent intravitreal injections, surgical insertion of an intraocular implant may be a more desirable, but more expensive option. Although the implant alone has also been shown to be more effective than intravenous ganciclovir in delaying progression of CMV retinitis (over 200 days [29,47] versus 60 to 70 days [43]), systemic antiviral therapy is also warranted to prevent the development of extraocular disease (23,25). Furthermore, the immediate and chronic complications associated with local antiviral therapy need to be considered.

Oral ganciclovir is an option for maintenance therapy if a patient is experiencing frequent complications associated with a permanent central line, or if the patient wishes to avoid the inconvenience of daily intravenous infusions. However, oral ganciclovir is not recommended for patients with immediately sight-threatening retinal lesions, because it may not achieve optimal concentrations (19). The oral formulation should be used only in patients with relatively intact gastrointestinal absorption. Other issues such as potential drug interactions, cost and patient compliance should be considered. More detailed guidelines on the appropriate use of oral ganciclovir have recently been described by the Canadian CMV Advisory Board (57).

In patients who experience frequent relapses despite high dose intravenous ganciclovir or who are experiencing unmanageable toxicities, switching to foscarnet is suggested. Generally, patients should receive induction doses of foscarnet (60 mg/kg every 8 h or 90 mg/kg every 12 h) until stabilization of retinitis before switching to maintenance therapy (120 mg/kg/day). As with ganciclovir, some patients may require higher doses to prevent disease progression.

In patients whose disease progresses despite trials of intravenous foscarnet and ganciclovir, a trial of the two agents in combination may be warranted (58-62). The optimal doses for combination therapy have not been clearly defined and should be tailored to individual patient response or toxicity. Initially, a trial of maintenance doses of both agents is acceptable in order to minimize toxicity. However, some patients may require induction doses of one or both agents in order to prevent disease progression. Although combination therapy may be more efficacious than either agent alone in terms of preventing retinitis progression and minimizing the rate of visual field loss (62), disadvantages include increased risk of toxicity, decreased convenience, increased cost and decreased quality of life (62).

Although preliminary data regarding the use of oral ganciclovir for CMV prophylaxis appear promising, the impact of widespread use on CMV resistance patterns is unclear. In addition, at a cost of approximately $50 per day, the pharmacoeconomic implications need to be considered. At this time, oral ganciclovir is not approved in Canada for the prevention of CMV disease.

**ADVERSE EFFECTS**

**Systemic administration:** The manufacturer reports that ganciclovir therapy was interrupted or discontinued in 52% of patients in clinical trials due to adverse effects (1). Reinstitution of treatment resulted in ganciclovir withdrawal or interruption in some cases.

The most frequently observed side effect is hematotoxicity. Neutropenia (absolute neutrophil count [ANC] less than 1x10^9/L) occurs in 38% of patients and thrombocytopenia (platelet count less than 50x10^9/L) in 19% of cases. Severe neutropenia (ANC less than 0.5x10^9/L) or thrombocytopenia (platelet count less than 25x10^9/L) necessitates treatment interruption until the bone marrow recovers. Anemia occurs in about 2% of cases. In general, hematological toxicity is reversible and evidence of marrow recovery occurs within three to seven days (1). The incidence of neutropenia and anemia appears to be slightly lower with the oral formulation than with the intravenous drug. This is likely a reflection of the lower serum concentrations achieved with the oral drug (19).

Throughout induction therapy, white blood cell counts and platelet counts should be done daily or every two days in those with a baseline ANC less than 1x10^9/L. During maintenance therapy complete blood counts and platelet counts should be done at least once weekly (1).

Ganciclovir-induced neutropenia may be decreased when sargramostim (GM-CSF) is co-administered (63,64). Grossberg et al (65) administered GM-CSF on a compassionate use basis to patients who became neutropenic while on ganciclovir. These patients were able to tolerate ganciclovir (5 to 10 mg/kg daily) for up to eight months, with prevention of retinitis in the majority of patients over the treatment period.

In a phase II, multicentre, randomized, open-label study (ACTG 073) (64), 53 patients with newly diagnosed, immediately sight-threatening CMV retinitis received ganciclovir (5 mg/kg every 12 h for 14 days, followed by 5 mg/kg/day maintenance) alone (n=29) or in combination with GM-CSF (n=24); no other potentially myelosuppressive agents were allowed during this phase. Patients randomized to the GM-CSF group received 1 to 8 μg/kg daily by subcutaneous injection to maintain an ANC of between 2.5 and 5x10^9/L. After 16 weeks, zidovudine 600 mg daily was added, and patients not already receiving GM-CSF were offered the agent if they became neutropenic (ANC less than 0.75x10^9/L). In the first 16 weeks, patients who received ganciclovir plus GM-CSF had significantly higher neutrophil counts and delayed time to first consecutive neutropenic event compared with patients on ganciclovir alone. Patients receiving GM-CSF also missed fewer scheduled ganciclovir doses, with a trend towards a delay in recurrence of CMV retinitis. All patients who were on zidovudine plus ganciclovir eventually received GM-CSF, with sustained effects on neutrophil count. By the end of the study, there was no difference between the groups with respect to retinitis progression. There was no evidence to suggest that GM-CSF consistently induced HIV proliferation, as determined by serial HIV p24 antigen measurements. The only adverse events that occurred more frequently in the ganciclovir plus GM-CSF group were higher serum creatinine levels, which were attributed to ganciclovir-related hematuria (64).

**Intravitreal administration:** The systemic adverse effects described above may also occur after intravitreal instillation. Furthermore, patients should be monitored for extraocular toxicities. The most significant systemic toxicity associated with intravitreal ganciclovir is nausea and vomiting, which occur in 20% of patients (65). Other systemic toxicities include an increase in basophils, increased serum lactate dehydrogenase, renal toxicity and hyperuricemia (65). However, none of these effects were severe enough to necessitate discontinuation of therapy (65). Intravitreal ganciclovir may induce systemic CMV reactivation. In one study, 92% of patients with CMV-negative vitreous who received intravitreal ganciclovir seroconverted (64). In another study, 71% of patients who had CMV negative vitreous at baseline seroconverted (66). Finally, intravitreal ganciclovir may induce systemic CMV reactivation, with a seroconversion rate of 39% (67). Intravitreal ganciclovir may induce systemic CMV reactivation, with a seroconversion rate of 39% (67).

**Local administration:** Local side effects associated with intraocular injections of ganciclovir include ocular pain, conjunctival injection, iritis, cystoid macular edema, retinal detachment, and cataract formation. In addition, there are reports of vitreous hemorrhage, retinal detachment and fibrotic tissue formation (68).

**Ocular implant**

Intraocular implants have been used to deliver ganciclovir to patients with CMV retinitis. The most commonly used implant is the Provisc Implant (42). This implant consists of a collagen gel matrix impregnated with ganciclovir. The gel is delivered subconjunctivally and is designed to slowly release ganciclovir over a period of 70 days (43). The implant is then typically removed.

Intravitreal ganciclovir may be an alternative to intravenous ganciclovir in neutropenic and/or thrombocytopenic patients who are intolerant to foscarnet, or it may be used in combination with systemic therapy to achieve greater control of CMV retinitis (56). For patients who do not wish to receive frequent intravitreal injections, surgical insertion of an intraocular implant may be a more desirable, but more expensive option. Although the implant alone has also been shown to be more effective than intravenous ganciclovir in delaying progression of CMV retinitis (over 200 days [29,47] versus 60 to 70 days [43]), systemic antiviral therapy is also warranted to prevent the development of extraocular disease (23,25). Furthermore, the immediate and chronic complications associated with local antiviral therapy need to be considered.

Oral ganciclovir is an option for maintenance therapy if a patient is experiencing frequent complications associated with a permanent central line, or if the patient wishes to avoid the inconvenience of daily intravenous infusions. However, oral ganciclovir is not recommended for patients with immediately sight-threatening retinal lesions, because it may not achieve optimal concentrations (19). The oral formulation should be used only in patients with relatively intact gastrointestinal absorption. Other issues such as potential drug interactions, cost and patient compliance should be considered. More detailed guidelines on the appropriate use of oral ganciclovir have recently been described by the Canadian CMV Advisory Board (57).

In patients who experience frequent relapses despite high dose intravenous ganciclovir or who are experiencing unmanageable toxicities, switching to foscarnet is suggested. Generally, patients should receive induction doses of foscarnet (60 mg/kg every 8 h or 90 mg/kg every 12 h) until stabilization of retinitis before switching to maintenance therapy (120 mg/kg/day). As with ganciclovir, some patients may require higher doses to prevent disease progression.

In patients whose disease progresses despite trials of intravenous foscarnet and ganciclovir, a trial of the two agents in combination may be warranted (58-62). The optimal doses for combination therapy have not been clearly defined and should be tailored to individual patient response or toxicity. Initially, a trial of maintenance doses of both agents is acceptable in order to minimize toxicity. However, some patients may require induction doses of one or both agents in order to prevent disease progression. Although combination therapy may be more efficacious than either agent alone in terms of preventing retinitis progression and minimizing the rate of visual field loss (62), disadvantages include increased risk of toxicity, decreased convenience, increased cost and decreased quality of life (62).

Although preliminary data regarding the use of oral ganciclovir for CMV prophylaxis appear promising, the impact of widespread use on CMV resistance patterns is unclear. In addition, at a cost of approximately $50 per day, the pharmacoeconomic implications need to be considered. At this time, oral ganciclovir is not approved in Canada for the prevention of CMV disease.
ganciclovir should be infused intravenously over a minimum of 1 h (maximum concentration of 10 mg/mL) to avoid excessive plasma concentrations, which may increase toxicity, tissue irritation and the incidence of phlebitis (1). Maintenance regimens include a dose of either 5 mg/kg once daily for seven days each week or 6 mg/kg once daily for five days of the week.

The dose of oral ganciclovir is 1 g orally tid with food for maintenance therapy of CMV retinitis. Use of this agent is not recommended in patients with sight-threatening retinitis or extraocular CMV disease, chronic diarrhea or vomiting, or in patients with potentially poor compliance (57).

For patients with renal impairment, refer to Table 1 for dosing guidelines. Ganciclovir should be given postdialysis on days when hemodialysis is performed. Dosing in dialysis should not exceed 1.25 mg/kg/24 h (1).

Intravitreal ganciclovir in doses of 200 to 400 µg in 0.1 mL of sterile normal saline administered every two to three days for up to 18 days followed by weekly maintenance doses have been used (56). To prepare the solution for intravitreal injection, a 500 mg vial should be diluted with 2.5 mL sterile water for injection, for a concentration of 200 µg/mL ganciclovir. Next, 0.1 mL (20 mg) of this solution is diluted to 10 mL in preservative-free normal saline for injection, to yield a final concentration of 200 µg/0.1 mL. The solution should be filtered with a 0.22 µm filter before use (56). The dose should be injected by an experienced ophthalmologist 3 to 4 mm from the corneoscleral limbus in the inferotemporal quadrant using a tuberculin syringe and a 30-gauge needle under topical anesthesia. Surgical implantation of a 1 µg/h sustained-release intraocular device is generally required every four to eight months (29). Implants are available from Chiron Vision (1-800-263-3557, Richmond Hill, Ontario) and cost approximately $5,000 each.

CONCLUSIONS

Ganciclovir is an effective agent in the treatment of CMV infections. Intravenous ganciclovir should be considered as first-line induction and maintenance therapy for CMV retinitis. Dosage adjustment is necessary in renal impairment. The most serious and frequently observed side effects are neutropenia and thrombocytopenia, which may necessitate interruption or discontinuation of therapy. Routine monitoring of hematological parameters is required. Caution should be employed when using ganciclovir in combination with other myelosuppressive drugs (including zidovudine) and ddI, because of the potential for pharmacokinetic or pharmacodynamic interactions. The development of novel formulations now allows this agent to be administered intraocularly as well as orally. Although these new products may be associated with increased patient convenience, they are not without their own associated risks and complications. Therefore, careful consideration of individual patient factors is required for the selection of the most appropriate route of drug administration. The utility of oral ganciclovir for the prevention of CMV disease in HIV patients requires further study.

REFERENCES


30. Frascino R, Gaines-Griffy K, Jung D, et al. Multiple dose crossover study of IV ganciclovir induction dose (5 mg/kg IV q12h) and didanosine (100 mg po q12h) in HIV-infected persons. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 17 to 20, 1995.


